Read more

February 26, 2024
1 min read
Save

ICL shows good outcomes from low to high myopia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FRANKFURT, Germany — The ICL allows for reliable, predictable correction of low to high degrees of myopia with similar safety and visual performance across all groups, according to a study on a large cohort.

This study provides evidence that “the ICL should not be reserved only for high degrees of myopia, and it performs extremely well across all degrees of myopia,” Milad Modabber, MD, said at the ESCRS winter meeting.

Milad Modabber, MD

A total of 1,332 patients who received the EVO/EVO+ ICL (STAAR Surgical) between 2016 and 2023 at the Herzig Eye Institute in Toronto were included. They were categorized as low (less than –6 D), intermediate (–6 D to –9 D) and high (more than –9 D) myopes. A toric lens was implanted in all patients (71%) with astigmatism above 1 D.

“In terms of uncorrected distance visual acuity, patients performed very well across all groups ... with comparable results,” Modabber said.

According to the results, 97.2% of eyes in the low myopia group, 96.3% in the intermediate myopia group and 86.5% in the high myopia group were within 0.5 D of target refraction, including eyes with 19 D to 20 D of myopia who were intentionally undercorrected. Corrected distance visual acuity was close to 20/20 in all groups.

Endothelial cell loss was less than 10% in 90% of the eyes. A mild IOP rise was seen in a few patients in the first week. The rate of secondary interventions was around 6%, with a low rate of laser vision correction enhancements, almost all in the high myopia group. Less than 2% of cases required ICL size adjustments, and only one patient required explantation due to glare and halos.

“And [that patient] threatened to sue us if we did not put the ICL back into the eye because he wanted the results so badly,” Modabber said.

His group is planning to continue the observation and move from retrospective to prospective studies.